Conor Fearon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Conor Fearon has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Tim Lynch
Dublin Neurological Institute, Mater Misericordiae University Hospital Dublin Ireland
7 shared publications Tim Lynch
Dublin Neurological Institute, Mater Misericordiae University Hospital, Dublin, Ireland
5 shared publications- Anthony E. Lang
Division of Neurology, Department of Medicine University of Toronto Toronto ON Canada
4 shared publications - Diana Angelika Olszewska
Department of Neurology Cork University Hospital Cork Ireland
4 shared publications - Richard B. Reilly
The University of Dublin
4 shared publications Anthony E. Lang
The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital & University of Toronto Toronto Ontario
3 shared publications
Latest Publications
- 1 August 2026
- Published by Springer Nature in Journal of Neural Transmission
- p. 1-15
Non-pharmacological and non-surgical therapies in advanced Parkinson’s disease: a narrative review and call to action
Non-pharmacological and non-surgical interventions are increasingly recognised as essential components of management of Parkinson’s disease (PD). However, as PD progresses to its advanced stages, limited mobility, cognitive impairment, treatment-refractory symptoms, and increasing dependence on care partners dominate. However, the evidence base for therapies in this stage becomes scarce. Most clinical practice guidelines and systematic reviews address PD as a whole, without highlighting specific recommendations tailored to advanced disease stage. This narrative review examines the current evidence for non-pharmacological and non-surgical therapies specifically in the context of advanced PD. This includes physiotherapy and exercise, freezing of gait management, dysphagia rehabilitation, nutrition and dietetics, neuropsychiatric care, autonomic dysfunction, pain management, and palliative care. We synthesised evidence from recent systematic reviews of clinical practice guidelines, scoping reviews of rehabilitation interventions in advanced PD, systematic reviews and meta-analyses of non-pharmacological treatments for specific symptom domains, the published literature on advanced PD management, and expert consensus. A recent systematic review identified 40 summary statements for non-pharmacological interventions in PD, yet these were developed without stage-specific differentiation. A scoping review of rehabilitation interventions specifically targeting advanced PD identified only 13 studies, predominantly focused on physical functioning. On the other hand, while interventions for freezing of gait, swallowing therapies, cognitive behavioural therapy for neuropsychiatric symptoms, non-invasive brain stimulation, non-pharmacological autonomic management, and multimodal exercise have demonstrated promise in PD, robust evidence for advanced PD remains largely absent. People with advanced PD represent a neglected population in non-pharmacological therapy research. There is a clear need for inclusion of people with advanced PD in guideline development and a holistic approach addressing factors such as demoralisation, caregiver strain, autonomic dysfunction, and spiritual wellbeing alongside physical rehabilitation.
- 1 August 2026
- Published by Springer Nature in Journal of Neural Transmission
- p. 1-15
Non-pharmacological and non-surgical therapies in advanced Parkinson’s disease: a narrative review and call to action
Non-pharmacological and non-surgical interventions are increasingly recognised as essential components of management of Parkinson’s disease (PD). However, as PD progresses to its advanced stages, limited mobility, cognitive impairment, treatment-refractory symptoms, and increasing dependence on care partners dominate. However, the evidence base for therapies in this stage becomes scarce. Most clinical practice guidelines and systematic reviews address PD as a whole, without highlighting specific recommendations tailored to advanced disease stage. This narrative review examines the current evidence for non-pharmacological and non-surgical therapies specifically in the context of advanced PD. This includes physiotherapy and exercise, freezing of gait management, dysphagia rehabilitation, nutrition and dietetics, neuropsychiatric care, autonomic dysfunction, pain management, and palliative care. We synthesised evidence from recent systematic reviews of clinical practice guidelines, scoping reviews of rehabilitation interventions in advanced PD, systematic reviews and meta-analyses of non-pharmacological treatments for specific symptom domains, the published literature on advanced PD management, and expert consensus. A recent systematic review identified 40 summary statements for non-pharmacological interventions in PD, yet these were developed without stage-specific differentiation. A scoping review of rehabilitation interventions specifically targeting advanced PD identified only 13 studies, predominantly focused on physical functioning. On the other hand, while interventions for freezing of gait, swallowing therapies, cognitive behavioural therapy for neuropsychiatric symptoms, non-invasive brain stimulation, non-pharmacological autonomic management, and multimodal exercise have demonstrated promise in PD, robust evidence for advanced PD remains largely absent. People with advanced PD represent a neglected population in non-pharmacological therapy research. There is a clear need for inclusion of people with advanced PD in guideline development and a holistic approach addressing factors such as demoralisation, caregiver strain, autonomic dysfunction, and spiritual wellbeing alongside physical rehabilitation.
- 14 March 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 485, 125873
Fronto-medial theta instability error signal correlates with postural sway in Parkinson's disease and progressive supranuclear palsy
- 14 March 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 485, 125873
Fronto-medial theta instability error signal correlates with postural sway in Parkinson's disease and progressive supranuclear palsy
- 5 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1192-1193
“Braking” Down Tremor: Reassessment of Tremor Pathomechanisms Considering Striatal Cholinergic Interneurons
- 5 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1192-1193
“Braking” Down Tremor: Reassessment of Tremor Pathomechanisms Considering Striatal Cholinergic Interneurons
- 20 November 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 68-69
Actor or Observer: The Sensorimotor Striatum Shapes Motor Output for Learned but Not Innate Motor Tasks
- 20 November 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 68-69
Actor or Observer: The Sensorimotor Striatum Shapes Motor Output for Learned but Not Innate Motor Tasks
- 19 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (4) , 1108-1110
Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data with Outpatient Dose Titration
- 19 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (4) , 1108-1110
Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data with Outpatient Dose Titration
- 5 October 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (1) , 4-16
Dementia with Lewy bodies: a practical guide to clinical diagnosis and management
Dementia with Lewy bodies (DLB) is a leading cause of late-life dementia which remains underdiagnosed and misdiagnosed, and is associated with significant diagnostic delay compared with non-DLB dementias. There is a pressing need for timely and accurate diagnosis of neurodegenerative disease with the emergence of pathologically targeted disease-modifying therapies. This review aims to provide neurologists with practical advice on the recognition of classical, prodromal and variant forms of DLB. We discuss the appropriate use of diagnostic modalities, along with advice on focused and practical management in the clinical setting.
- 5 October 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (1) , 4-16
Dementia with Lewy bodies: a practical guide to clinical diagnosis and management
Dementia with Lewy bodies (DLB) is a leading cause of late-life dementia which remains underdiagnosed and misdiagnosed, and is associated with significant diagnostic delay compared with non-DLB dementias. There is a pressing need for timely and accurate diagnosis of neurodegenerative disease with the emergence of pathologically targeted disease-modifying therapies. This review aims to provide neurologists with practical advice on the recognition of classical, prodromal and variant forms of DLB. We discuss the appropriate use of diagnostic modalities, along with advice on focused and practical management in the clinical setting.
- 6 August 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2368-2369
Neuro‐Ophthalmological Manifestations of Episodic Ataxia Type 2 Due to a Novel CACNA1A Mutation
- 6 August 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2368-2369
Neuro‐Ophthalmological Manifestations of Episodic Ataxia Type 2 Due to a Novel CACNA1A Mutation
- Open Access
Determining Falls Risk in People with Parkinson’s Disease Using Wearable Sensors: A Systematic Review
A prior history of falls remains the strongest predictor of future falls in individuals with Parkinson’s disease (PD). There are limited biomarkers available to identify falls risk before falls begin to occur. The aim of this review is to investigate if features associated with falls risk may be detected by wearable sensors in patients with PD. A systematic search of the MEDLINE, EMBASE, Cochrane, and Cinahl databases was performed. Key quality criteria include sample size adequacy, data collection procedures, and the clarity of statistical analyses. The data from each included study were extracted into defined data extraction spreadsheets. Results were synthesized in a narrative manner. Twenty-four articles met the inclusion criteria. Of these, twelve measured falls prospectively, while the remaining relied on retrospective history. The definition of a “faller” varied across studies. Most assessments were conducted in a clinical setting (18/24). There was considerable variability in sensor placement and mobility tasks assessed. The most common sensor-derived measures that significantly differentiated “fallers” from “non-fallers” in Parkinson’s disease included gait variability, stride variability, trunk motion, walking speed, and stride length.
Open AccessDetermining Falls Risk in People with Parkinson’s Disease Using Wearable Sensors: A Systematic Review
A prior history of falls remains the strongest predictor of future falls in individuals with Parkinson’s disease (PD). There are limited biomarkers available to identify falls risk before falls begin to occur. The aim of this review is to investigate if features associated with falls risk may be detected by wearable sensors in patients with PD. A systematic search of the MEDLINE, EMBASE, Cochrane, and Cinahl databases was performed. Key quality criteria include sample size adequacy, data collection procedures, and the clarity of statistical analyses. The data from each included study were extracted into defined data extraction spreadsheets. Results were synthesized in a narrative manner. Twenty-four articles met the inclusion criteria. Of these, twelve measured falls prospectively, while the remaining relied on retrospective history. The definition of a “faller” varied across studies. Most assessments were conducted in a clinical setting (18/24). There was considerable variability in sensor placement and mobility tasks assessed. The most common sensor-derived measures that significantly differentiated “fallers” from “non-fallers” in Parkinson’s disease included gait variability, stride variability, trunk motion, walking speed, and stride length.
- Open Access
- 11 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2216
Treatment of Apathy in Parkinson’s Disease and Implications for Underlying Pathophysiology
Apathy is a prevalent and highly debilitating non-motor symptom of Parkinson’s disease (PD) that is often overlooked in clinical practice due to its subtle nature. This review aims to provide a comprehensive overview of the current evidence for the treatment of apathy in PD, highlighting recent advancements and emerging therapeutic avenues. In this review, we analyse a diverse array of treatment strategies for apathy in PD, including pharmacological interventions, non-pharmacological approaches, and emerging neuromodulation techniques. We evaluate the efficacy, safety, and limitations of established pharmacotherapies, such as dopaminergic agents, antidepressants, and cognitive enhancers. Additionally, we examine the promising role of non-pharmacological interventions, encompassing psychotherapies and behavioural interventions, in ameliorating apathetic symptoms. Furthermore, this review explores the effects of neuromodulation techniques on apathy, including the modulation of apathy via deep brain stimulation and emerging data on the potential influence of transcranial magnetic stimulation (TMS) on apathy in PD. Ultimately, a deeper understanding of effective treatment strategies for apathy has the potential to significantly improve the quality of life and overall well-being of individuals living with PD.
- 11 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2216
Open AccessTreatment of Apathy in Parkinson’s Disease and Implications for Underlying Pathophysiology
Apathy is a prevalent and highly debilitating non-motor symptom of Parkinson’s disease (PD) that is often overlooked in clinical practice due to its subtle nature. This review aims to provide a comprehensive overview of the current evidence for the treatment of apathy in PD, highlighting recent advancements and emerging therapeutic avenues. In this review, we analyse a diverse array of treatment strategies for apathy in PD, including pharmacological interventions, non-pharmacological approaches, and emerging neuromodulation techniques. We evaluate the efficacy, safety, and limitations of established pharmacotherapies, such as dopaminergic agents, antidepressants, and cognitive enhancers. Additionally, we examine the promising role of non-pharmacological interventions, encompassing psychotherapies and behavioural interventions, in ameliorating apathetic symptoms. Furthermore, this review explores the effects of neuromodulation techniques on apathy, including the modulation of apathy via deep brain stimulation and emerging data on the potential influence of transcranial magnetic stimulation (TMS) on apathy in PD. Ultimately, a deeper understanding of effective treatment strategies for apathy has the potential to significantly improve the quality of life and overall well-being of individuals living with PD.